Kenneth W. Perry - Concepedia

Author

Kenneth W. Perry

Also Known As

K Perry, K W Perry, K. Perry, K. W. PERRY, K. W. Perry, K.W. PERRY, K.W. Perry, KW Perry, Kenneth Perry, Kenneth W Perry

143

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)

About

Kenneth W. Perry is an author at Eli Lilly (United States) specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	35	57	4.5K
2	Social Sciences	31	45	3.9K
3	Health Sciences	4	4	319
4	Engineering	2	2	23
5	Natural Sciences	1	1	46

Kenneth W. Perry

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Vasopressin/Serotonin Interactions in the Anterior Hypothalamus Control Aggressive Behavior in Golden Hamsters Craig F. Ferris, Richard H. Melloni, G. A. KOPPEL, Journal of Neuroscience Social SciencesAggressive BehaviorGolden HamstersNeuroendocrine MechanismHypothalamic Peptide	1997	496
Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex Frank P. Bymaster, Wei Zhang, Petra A. Carter, Psychopharmacology Psychoactive DrugPsychiatryNeurophysiologyPrefrontal CortexMedicine	2002	334
The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions Eleni T. Tzavara, Richard J. Davis, Kenneth W. Perry, British Journal of Pharmacology	2003	269
Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatum Kenneth W. Perry, Ray W. Fuller Life Sciences Psychoactive DrugNeurophysiologyMedicineDopamine ConcentrationMicrodialysis Fluid	1992	217
Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat Chad J. Swanson, Kenneth W. Perry, Susanne Koch-Krueger, Neuropharmacology NeuropsychologySeveral Brain RegionsAttention Deficit/hyperactivityCognitive NeurosciencePsychiatry	2006	214
Effect of an uptake inhibitor on serotonin metabolism in rat brain: Studies with 3-(p-trifluoromethylphenoxy)-n-methyl-3-phenylpropylamine (Lilly 110140) Ray W. Fuller, Kenneth W. Perry, Bryan B. Molloy Life Sciences Serotonin MetabolismMedicinePsychopharmacologyNeuropharmacologyExperimental Pharmacology	1974	206
Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum Ximing Li, Kenneth W. Perry, David T. Wong, Psychopharmacology NeuropsychologyOlanzapine IncreasesPsychotropic MedicationRat Prefrontal CortexPsychopharmacology	1998	191
M <sub>4</sub> muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related central nervous system pathologies Eleni T. Tzavara, Frank P. Bymaster, Richard J. Davis, The FASEB Journal Dopaminergic NeurotransmissionSynaptic TransmissionNeurotransmissionSynaptic SignalingCholinergic Function	2004	190
Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats Simon Xi-Ming Li, Kenneth W. Perry, David T. Wong Neuropharmacology Mesocorticolimbic AreasNeurophysiologyNeuroanatomyNorepinephrine ConcentrationsPhysiology	2002	156
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders Linda M. Rorick‐Kehn, Bryan G. Johnson, Karen M. Knitowski, Psychopharmacology Molecular PharmacologyPsychoactive DrugPsychiatric DisordersPsychiatryMedicine	2007	156

Page 1